FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176807750> ?p ?o ?g. }

• W3176807750 endingPage "2716" @default.
• W3176807750 startingPage "2707" @default.
• W3176807750 abstract "The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients." @default.
• W3176807750 created "2021-07-05" @default.
• W3176807750 creator A5000559744 @default.
• W3176807750 creator A5001414926 @default.
• W3176807750 creator A5011725019 @default.
• W3176807750 creator A5011863718 @default.
• W3176807750 creator A5011897271 @default.
• W3176807750 creator A5011903306 @default.
• W3176807750 creator A5014598737 @default.
• W3176807750 creator A5015498967 @default.
• W3176807750 creator A5017565182 @default.
• W3176807750 creator A5019395397 @default.
• W3176807750 creator A5024906714 @default.
• W3176807750 creator A5027335873 @default.
• W3176807750 creator A5028510513 @default.
• W3176807750 creator A5029448872 @default.
• W3176807750 creator A5034649716 @default.
• W3176807750 creator A5035277761 @default.
• W3176807750 creator A5037925743 @default.
• W3176807750 creator A5039142430 @default.
• W3176807750 creator A5039235274 @default.
• W3176807750 creator A5040956966 @default.
• W3176807750 creator A5044929990 @default.
• W3176807750 creator A5045699520 @default.
• W3176807750 creator A5045755743 @default.
• W3176807750 creator A5049888706 @default.
• W3176807750 creator A5056858207 @default.
• W3176807750 creator A5057145264 @default.
• W3176807750 creator A5058238162 @default.
• W3176807750 creator A5059708573 @default.
• W3176807750 creator A5060545994 @default.
• W3176807750 creator A5061317839 @default.
• W3176807750 creator A5062182046 @default.
• W3176807750 creator A5063558334 @default.
• W3176807750 creator A5066826766 @default.
• W3176807750 creator A5067271311 @default.
• W3176807750 creator A5067544558 @default.
• W3176807750 creator A5075804920 @default.
• W3176807750 creator A5081277564 @default.
• W3176807750 creator A5083085650 @default.
• W3176807750 creator A5085146093 @default.
• W3176807750 date "2021-07-01" @default.
• W3176807750 modified "2023-10-18" @default.
• W3176807750 title "Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas" @default.
• W3176807750 cites W1971211622 @default.
• W3176807750 cites W2041498582 @default.
• W3176807750 cites W2069832110 @default.
• W3176807750 cites W2084433006 @default.
• W3176807750 cites W2089197481 @default.
• W3176807750 cites W2127018518 @default.
• W3176807750 cites W2140085064 @default.
• W3176807750 cites W2188955550 @default.
• W3176807750 cites W2305142474 @default.
• W3176807750 cites W2532606512 @default.
• W3176807750 cites W2744261860 @default.
• W3176807750 cites W2773804840 @default.
• W3176807750 cites W2806889830 @default.
• W3176807750 cites W2901295394 @default.
• W3176807750 cites W2903062212 @default.
• W3176807750 cites W2934686121 @default.
• W3176807750 cites W2944689312 @default.
• W3176807750 cites W2948517706 @default.
• W3176807750 cites W2954789649 @default.
• W3176807750 cites W2974108516 @default.
• W3176807750 cites W2984056678 @default.
• W3176807750 cites W2984927918 @default.
• W3176807750 cites W2986196170 @default.
• W3176807750 cites W2993918267 @default.
• W3176807750 cites W3024978145 @default.
• W3176807750 cites W3033403632 @default.
• W3176807750 cites W3035551042 @default.
• W3176807750 cites W3037322433 @default.
• W3176807750 cites W3043369050 @default.
• W3176807750 cites W3044532926 @default.
• W3176807750 cites W3088753895 @default.
• W3176807750 cites W3092023747 @default.
• W3176807750 cites W3094763563 @default.
• W3176807750 cites W3095704533 @default.
• W3176807750 cites W3096548119 @default.
• W3176807750 cites W3112524531 @default.
• W3176807750 doi "https://doi.org/10.1182/bloodadvances.2020004155" @default.
• W3176807750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8288676" @default.
• W3176807750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34196677" @default.
• W3176807750 hasPublicationYear "2021" @default.
• W3176807750 type Work @default.
• W3176807750 sameAs 3176807750 @default.
• W3176807750 citedByCount "45" @default.
• W3176807750 countsByYear W31768077502021 @default.
• W3176807750 countsByYear W31768077502022 @default.
• W3176807750 countsByYear W31768077502023 @default.
• W3176807750 crossrefType "journal-article" @default.
• W3176807750 hasAuthorship W3176807750A5000559744 @default.
• W3176807750 hasAuthorship W3176807750A5001414926 @default.
• W3176807750 hasAuthorship W3176807750A5011725019 @default.
• W3176807750 hasAuthorship W3176807750A5011863718 @default.
• W3176807750 hasAuthorship W3176807750A5011897271 @default.
• W3176807750 hasAuthorship W3176807750A5011903306 @default.
• W3176807750 hasAuthorship W3176807750A5014598737 @default.

• next